GHA
UTHR icon

GW Henssler & Associates’s United Therapeutics UTHR Stock Holding History

GW Henssler & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Sell
508
-210
-29% -$118K 0.01% 195
2026
Q1 		$426K Sell
718
-5
-0.7% -$2.49K 0.02% 143
2025
Q4 		$352K Sell
723
-103
-12% -$48K 0.02% 154
2025
Q3 		$346K Buy
826
+123
+17% +$41.4K 0.02% 149
2025
Q2 		$202K Sell
703
-7
-1% -$2.09K 0.01% 177
2025
Q1 		$219K Sell
710
-1
-0.1% -$343 0.01% 161
2024
Q4 		$255K Hold
711
– – 0.01% 139
2024
Q3 		$255K Buy
+711
New +$240K 0.01% 143
2023
Q3 		– Sell
-1,324
Closed -$292K – 270
2023
Q2 		$292K Hold
1,324
– – 0.02% 151
2023
Q1 		$297K Buy
1,324
+12
+0.9% +$2.96K 0.02% 170
2022
Q4 		$365K Hold
1,312
– – 0.03% 132
2022
Q3 		$275K Sell
1,312
-182
-12% -$40.7K 0.02% 159
2022
Q2 		$352K Sell
1,494
-1,826
-55% -$371K 0.03% 128
2022
Q1 		$596K Buy
3,320
+5
+0.2% +$953 0.04% 104
2021
Q4 		$716K Buy
+3,315
New +$651K 0.05% 108
2021
Q3 		– Sell
-3,055
Closed -$548K – 216
2021
Q2 		$548K Buy
3,055
+73
+2% +$13.9K 0.04% 116
2021
Q1 		$499K Hold
2,982
– – 0.04% 124
2020
Q4 		$453K Buy
2,982
+16
+0.5% +$2.1K 0.03% 129
2020
Q3 		$300K Buy
2,966
+105
+4% +$11.5K 0.03% 153
2020
Q2 		$346K Sell
2,861
-1,488
-34% -$167K 0.03% 123
2020
Q1 		$412K Sell
4,349
-255
-6% -$24.2K 0.04% 114
2019
Q4 		$406K Buy
4,604
+804
+21% +$70.7K 0.03% 160
2019
Q3 		$303K Sell
3,800
-600
-14% -$48.3K 0.03% 178
2019
Q2 		$343K Buy
4,400
+928
+27% +$86.8K 0.03% 173
2019
Q1 		$408K Buy
+3,472
New +$405K 0.04% 152
2015
Q3 		– Sell
-1,314
Closed -$229K – 174
2015
Q2 		$229K Sell
1,314
-161
-11% -$29K 0.02% 145
2015
Q1 		$254K Buy
+1,475
New +$225K 0.03% 151

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

GW Henssler & Associates's UTHR Position: Q2 2026 in Review

GW Henssler & Associates reduced its United Therapeutics (UTHR) stake by 29% in Q2 2026, selling an estimated $118K and leaving 508 shares worth $275K. The position accounts for 0.01% of the portfolio, ranked #195.

GW Henssler & Associates first reported a position in UTHR in Q1 2015 and has held it in 27 quarters since. The position peaked at $716K in Q4 2021. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • GW Henssler & Associates held 508 shares of United Therapeutics worth $275K as of Q2 2026.
  • GW Henssler & Associates sold 210 United Therapeutics shares in Q2 2026, an estimated $118K.
  • United Therapeutics made up 0.01% of GW Henssler & Associates's portfolio in Q2 2026, its #195 holding.
  • GW Henssler & Associates first reported a position in United Therapeutics in Q1 2015 and has held it in 27 quarters since.
  • GW Henssler & Associates's United Therapeutics position peaked at $716K in Q4 2021.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on GW Henssler & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.